Rixubis FDA Approval History
FDA Approved: Yes (First approved June 26, 2013)
Brand name: Rixubis
Generic name: coagulation factor IX (recombinant)
Dosage form: Injection
Company: Baxter International Inc.
Treatment for: Hemophilia B
Rixubis (coagulation factor IX, recombinant) is an antihemophilic factor indicated for the control and prevention of bleeding episodes in adults with hemophilia B.
Development timeline for Rixubis
|Jun 27, 2013||Approval FDA Approves Rixubis - First Recombinant Coagulation Factor IX For Use in Preventing Bleeding Episodes|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.